ETOPOSIDE TEVA 20 mg/ml

DRUG4 trials

Sponsors

Fondazione IRCCS Istituto Nazionale Dei Tumori, Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., Institut Curie

Conditions

Extensive-Stage Small-Cell Lung Cancer (ES SCLC)Relapsed or Refractory Peripheral T-cell LymphomasRetinoblastoma

Phase 2

Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas

Active, not recruitingCTIS2024-513295-18-00

Fondazione IRCCS Istituto Nazionale Dei TumoriRelapsed or Refractory Peripheral T-cell Lymphomas

Start: 2022-08-10Target: 30Updated: 2025-11-18

Phase 2 trial of Translational approach to first line cHemoimmunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensive-Stage Small-Cell Lung CanceR (THOR trial)

RecruitingCTIS2024-514666-39-00

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

Start: 2023-03-16Target: 60Updated: 2025-06-11

RB SFCE 2009 : Adjuvant treatment in extensive unilateral retinoblastoma primary enucleated

Active, not recruitingCTIS2024-514844-10-00

Institut CurieRetinoblastoma

Start: 2010-03-18Target: 195Updated: 2025-07-01

"RETINO 2011" : Conservative treatment of patients with retinoblastoma

RecruitingCTIS2024-517275-21-00

Institut CurieRetinoblastoma

Start: 2012-02-20Target: 133Updated: 2024-09-05